Evidence map›Paper›PMID 39132977›Full record

ArticleEuropean journal of neurology2024

Brain amyloid load, subjective memory complaints, and cognitive trajectories in older individuals at risk for dementia.

Gazi Saadmaan, Anette Hall, Tiia Ngandu, Nina Kemppainen, Francesca Mangialasche, Gayle M Wittenberg, Anna Matton, Juha O Rinne, Miia Kivipelto, Alina Solomon

Abstract read
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gazi SaadmaanDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0002-0925-7609
Anette HallDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Tiia NganduDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institute, Stockholm, Sweden.
Nina KemppainenTurku PET Center, University of Turku, Turku, Finland.
Francesca MangialascheDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institute, Stockholm, Sweden.
Gayle M WittenbergNeuroscience, Data Science, & Digital Health, Janssen Research & Development, Titusville, New Jersey, USA.
Anna MattonDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institute, Stockholm, Sweden.
Juha O RinneTurku PET Center, University of Turku, Turku, Finland.
Miia KivipeltoDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institute, Stockholm, Sweden.
Alina SolomonDepartment of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

Funding

AlzheimerfondenAlzheimer's Research and Prevention Foundation (US)EU Joint Programme - Neurodegenerative Disease Research (JPND) EURO-FINGERS and Multi-MeMo grants; ERA PerMed Pattern-Cog grantEuropean Research Council grant 804371Juho Vainio Foundation (Finland)Kela (Finland)Ministry of Education and Culture (Finland)NordForskRegion Stockholm (ALF, Sweden); Center for Innovative Medicine (CIMED) at Karolinska Institute (Sweden); Stiftelsen Stockholms sjukhem (Sweden); Knut and Alice Wallenberg Foundation (Sweden); Swedish Research Council for Health, Working Life and Welfare (FORTE);Research collaboration between Finnish Institute for Health and Welfare, Karolinska Institutet and Janssen Pharmaceutica NV (research project "Prediction modelling, identification and validation of novel molecular signatures of dementia")Research Council of FinlandSigrid Juséliuksen SäätiöVetenskapsrådet
6 · The paper itself

Abstract

background and purposeThis study evaluated associations of brain amyloid with 2-year objective and subjective cognitive measures in a trial-ready older general population at risk for dementia.

methodsForty-eight participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability underwent

resultsMean age was 71.4 ± 5.06 years, and 20 participants (42%) had positive baseline PiB-PET scans. Amyloid positivity was associated with lower NTB executive function at baseline and less favorable 2-year NTB total score and memory trajectories, but not with other objective or subjective cognitive measures. Overall, there was little cognitive decline during 2 years.

conclusionsAmyloid accumulation may affect objective but not necessarily subjective cognition from a very early at-risk stage, although substantial decline likely requires >2 years to occur.

Indexed as

BrainDementiaNeuropsychological TestsPositron-Emission TomographyAgedAged, 80 and overAniline CompoundsFemaleHumansMaleMemory DisordersThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAniline CompoundsThiazolesAlzheimer diseaseamyloidclinical trialcognitionPiB‐PET

Identifiers

PMID39132977
PMCPMC11554848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.